Evaluation of Antiproliferative Activity and Molecular Modeling Studies of Some Novel Benzimidazolone-Bridged Hybrid Compounds
Okan Güven, Emre Menteşe, Fatih Yılmaz, Adem Güner, Mustafa Emirik, Nedime Çalışkan, Dmytro Khylyuk · 2025
Read Evaluation of Antiproliferative Activity and Molecular Modeling Studies of Some Novel Benzimidazolone-Bridged Hybrid Compounds by Okan Güven, Emre Menteşe, Fatih Yılmaz, Adem Güner, Mustafa Emirik, Nedime Çalışkan, Dmytro Khylyuk (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12735921.txt.
Description
Okan Güven and co-authors design and test a new family of hybrid molecules against cancer cells. Their 2025 paper builds compounds on a benzimidazolone bridge, fused with parts drawn from thiophene, furan, and other drug-like fragments. Cancer's global toll frames the work: nearly ten million deaths in 2022, with more projected.
The team made the compounds, confirmed their structures, and dosed them against lung, breast, and cervical cancer cells plus a normal kidney line. Several killed cancer cells in a dose-dependent way, with cervical cells the most sensitive. Adding one ring type or a coumarin part sharply improved both strength and selectivity, giving low doses needed and sparing normal cells two to three times over. Computer docking against two cancer-relevant proteins supported the results. The authors name the best compounds as leads worth developing.
Catalog record
| CREATOR | Okan Güven, Emre Menteşe, Fatih Yılmaz, Adem Güner, Mustafa Emirik, Nedime Çalışkan, Dmytro Khylyuk |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 84 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |